On September 3, 2025 Nektar Therapeutics (Nasdaq: NKTR) reported that the company will be webcasting its participation in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York City and the Stifel Virtual Immunology and Inflammation Forum being held September 15-16, 2025 (Press release, Nektar Therapeutics, SEP 3, 2025, View Source [SID1234655742]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025 – webcast to be available at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time – link here

Stifel 2025 Virtual Immunology and Inflammation Forum on Monday, September 15, 2025 – webcast to be available at 2:30 p.m. Eastern Time / 11:30 a.m. Pacific Time – link here
The presentations will be accessible via the webcast links above as well as on the Investor Events section of the Nektar website: View Source Replays of the presentations will be available for 30 days.

If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.

On September 3, 2025 IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, reported the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for IDE892, a potential best-in-class MTA-cooperative inhibitor of PRMT5 (Press release, Ideaya Biosciences, SEP 3, 2025, View Source [SID1234655741]). The company is targeting to begin a Phase 1 dose escalation trial of IDE892 in MTAP-deleted lung cancer in the fourth quarter of 2025, with the goal of advancing into combination trials with IDE397, IDEAYA’s proprietary MAT2A inhibitor, in the first half of 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Approximately 15-20% of non-small cell lung cancer (NSCLC) is MTAP-deleted. Extensive studies indicate that elevated MTA/SAM ratios in MTAP-deleted cancers create a tumor-specific vulnerability to MTA-cooperative PRMT5 inhibition. This effect is substantially enhanced in combination with MAT2A inhibition, leading to an important combination therapy opportunity in an area of substantial unmet need. In addition to MTAP-deleted lung cancer, IDEAYA will target to clinically evaluate other high priority MTAP solid tumor indications as both IDE892 monotherapy and in combination with IDE397.

"We are excited to advance IDE892 into clinical studies for patients with MTAP-deleted lung cancer, where we believe the inhibition of PRMT5 in combination with MAT2A could have synergistic anti-tumor activity," said Michael White, Chief Scientific Officer, IDEAYA Biosciences. "IDE892 is the culmination of a comprehensive optimization of the biophysical and pharmacokinetic properties required to maximize therapeutic benefit as a combination partner with IDE397, and to generate a potential best-in-class MTA-cooperative PRMT5 inhibitor profile."

Registration for IDEAYA’s 10-Year Anniversary R&D Day can be accessed here or at the investors section of the IDEAYA website at View Source

On September 3, 2025 Galvanize ("Galvanize") Therapeutics, Inc, a commercial-stage medical technology company pioneering pulsed electric field (PEF) therapies for oncology and chronic lung disease reported it has successfully raised an oversubscribed $100 million Series C financing (Press release, Galvanize Therapeutics, SEP 3, 2025, View Source [SID1234655740]). The round was led by Sofinnova Partners, a leading European life sciences venture capital firm, with participation from a global syndicate of top-tier investors including Norwest Venture Partners, Elevage Medical Technologies, Ally Bridge Group, Perceptive Xontogeny Venture Fund, Janus Henderson Investors and Longaeva. Existing investors Fidelity Management & Research Company, T. Rowe Price, Gilmartin Capital, Intuitive Surgical and the company’s founding investor, Apple Tree Partners ("ATP"), also participated in the round.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Proceeds from the financing will be used to expand the company’s commercial footprint and advance its clinical and development activities related to Aliya PEF in solid tumors and RheOx therapy for chronic bronchitis. The company will also use the funds to continue to innovate its novel PEF platform, a non-pharmacologic intervention which uses non-thermal, short-duration, highly focused electrical pulses that destabilize cellular pathologic processes in hopes of changing the disease trajectory for these patients.

Concurrent with the financing, Doug Godshall, former CEO of Shockwave Medical and HeartWare International, was appointed Chairman and CEO of Galvanize Therapeutics, while Jonathan Waldstreicher assumed the role of President and Chief Strategy Officer.

Mr. Godshall commented: "I began following Galvanize in 2016 and became actively involved when I joined the board as Chairman in 2021. I have grown increasingly enthusiastic about the company’s prospects over the last year as the team continued advancing our portfolio and commencing our initial commercial efforts. Galvanize’s Aliya and RheOx technologies hold great promise in the fields of solid tumor oncology and chronic bronchitis. There are millions of patients who are underserved by today’s largely pharmaceutical approaches, and I feel fortunate to be able to join the team as we seek to meaningfully improve the outcomes of those who are suffering with these chronic diseases."

As part of the financing, Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, Zack Scott, M.D., General Partner at Norwest, and David Lewis, Managing Partner at Gilmartin Capital, have joined the Board of Directors.

Mr. Papiernik added: "We have closely followed Galvanize for years and are impressed by its technology, strong team, and execution. Partnering again with Doug after our Shockwave success, and working with such a powerful syndicate, was an opportunity we couldn’t refuse. We believe Galvanize’s PEF program could significantly improve treatment and benefit patients with serious unmet needs."

On September 3, 2025 Galvanize ("Galvanize") Therapeutics, Inc, a commercial-stage medical technology company pioneering pulsed electric field (PEF) therapies for oncology and chronic lung disease reported it has successfully raised an oversubscribed $100 million Series C financing (Press release, Galvanize Therapeutics, SEP 3, 2025, View Source [SID1234655740]). The round was led by Sofinnova Partners, a leading European life sciences venture capital firm, with participation from a global syndicate of top-tier investors including Norwest Venture Partners, Elevage Medical Technologies, Ally Bridge Group, Perceptive Xontogeny Venture Fund, Janus Henderson Investors and Longaeva. Existing investors Fidelity Management & Research Company, T. Rowe Price, Gilmartin Capital, Intuitive Surgical and the company’s founding investor, Apple Tree Partners ("ATP"), also participated in the round.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Proceeds from the financing will be used to expand the company’s commercial footprint and advance its clinical and development activities related to Aliya PEF in solid tumors and RheOx therapy for chronic bronchitis. The company will also use the funds to continue to innovate its novel PEF platform, a non-pharmacologic intervention which uses non-thermal, short-duration, highly focused electrical pulses that destabilize cellular pathologic processes in hopes of changing the disease trajectory for these patients.

Concurrent with the financing, Doug Godshall, former CEO of Shockwave Medical and HeartWare International, was appointed Chairman and CEO of Galvanize Therapeutics, while Jonathan Waldstreicher assumed the role of President and Chief Strategy Officer.

Mr. Godshall commented: "I began following Galvanize in 2016 and became actively involved when I joined the board as Chairman in 2021. I have grown increasingly enthusiastic about the company’s prospects over the last year as the team continued advancing our portfolio and commencing our initial commercial efforts. Galvanize’s Aliya and RheOx technologies hold great promise in the fields of solid tumor oncology and chronic bronchitis. There are millions of patients who are underserved by today’s largely pharmaceutical approaches, and I feel fortunate to be able to join the team as we seek to meaningfully improve the outcomes of those who are suffering with these chronic diseases."

As part of the financing, Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, Zack Scott, M.D., General Partner at Norwest, and David Lewis, Managing Partner at Gilmartin Capital, have joined the Board of Directors.

Mr. Papiernik added: "We have closely followed Galvanize for years and are impressed by its technology, strong team, and execution. Partnering again with Doug after our Shockwave success, and working with such a powerful syndicate, was an opportunity we couldn’t refuse. We believe Galvanize’s PEF program could significantly improve treatment and benefit patients with serious unmet needs."

On September 3, 2025 Galvanize ("Galvanize") Therapeutics, Inc, a commercial-stage medical technology company pioneering pulsed electric field (PEF) therapies for oncology and chronic lung disease reported it has successfully raised an oversubscribed $100 million Series C financing (Press release, Galvanize Therapeutics, SEP 3, 2025, View Source [SID1234655740]). The round was led by Sofinnova Partners, a leading European life sciences venture capital firm, with participation from a global syndicate of top-tier investors including Norwest Venture Partners, Elevage Medical Technologies, Ally Bridge Group, Perceptive Xontogeny Venture Fund, Janus Henderson Investors and Longaeva. Existing investors Fidelity Management & Research Company, T. Rowe Price, Gilmartin Capital, Intuitive Surgical and the company’s founding investor, Apple Tree Partners ("ATP"), also participated in the round.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Proceeds from the financing will be used to expand the company’s commercial footprint and advance its clinical and development activities related to Aliya PEF in solid tumors and RheOx therapy for chronic bronchitis. The company will also use the funds to continue to innovate its novel PEF platform, a non-pharmacologic intervention which uses non-thermal, short-duration, highly focused electrical pulses that destabilize cellular pathologic processes in hopes of changing the disease trajectory for these patients.

Concurrent with the financing, Doug Godshall, former CEO of Shockwave Medical and HeartWare International, was appointed Chairman and CEO of Galvanize Therapeutics, while Jonathan Waldstreicher assumed the role of President and Chief Strategy Officer.

Mr. Godshall commented: "I began following Galvanize in 2016 and became actively involved when I joined the board as Chairman in 2021. I have grown increasingly enthusiastic about the company’s prospects over the last year as the team continued advancing our portfolio and commencing our initial commercial efforts. Galvanize’s Aliya and RheOx technologies hold great promise in the fields of solid tumor oncology and chronic bronchitis. There are millions of patients who are underserved by today’s largely pharmaceutical approaches, and I feel fortunate to be able to join the team as we seek to meaningfully improve the outcomes of those who are suffering with these chronic diseases."

As part of the financing, Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, Zack Scott, M.D., General Partner at Norwest, and David Lewis, Managing Partner at Gilmartin Capital, have joined the Board of Directors.

Mr. Papiernik added: "We have closely followed Galvanize for years and are impressed by its technology, strong team, and execution. Partnering again with Doug after our Shockwave success, and working with such a powerful syndicate, was an opportunity we couldn’t refuse. We believe Galvanize’s PEF program could significantly improve treatment and benefit patients with serious unmet needs."